The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
The summit will bring together 1,200+ delegates, 100+ international faculty from 25 countries
Multidisciplinary team expansion brings integrated medical, surgical, and radiation oncology services under one roof
New facility offers genetic testing, counselling and personalised treatment plans to enable early diagnosis and precision-led care
The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Subscribe To Our Newsletter & Stay Updated
